IAPS Reside CTITIO 03 MAR 2006

Express Mail No. EV 686 022 789 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Gustafsson et al. Confirmation No.: To be assigned Serial No.: 10/566,954; national stage of Art Unit: To be assigned PCT/US04/024751, filed July 30, 2004 Filed: January 31, 2006 Examiner: To be assigned For: SYSTEMS AND METHODS FOR Attorney Docket No.: 11548-003-999 ANTIBODY ENGINEERING

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

2.

冈

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

1. Enclosures accompanying this Information Disclosure Statement are: la. A list of all patents, publications, applications, or other information submitted for consideration by the office. 1b. A legible copy of: Each publication or that portion which caused it to be listed on the PTO-1449; For each cited pending unpublished U.S. application, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion that have been checked to be unavailable at the USPTO's private PAIR system; An English language copy of search report(s) from a counterpart foreign application or PCT International Search Report; Explanations of relevancy (ATTACHMENT 1(d), hereto) or English language abstracts of the non-English language publications; All other information or portion which caused it to be listed on the PTO-1449. Pursuant to 37 C.F.R. § 1.98(a)(2)(ii), copies of the cited U.S. patents and U.S. 1c. patent application publications are not submitted herewith unless required by the office. 1d. Pursuant to 1287 OG 163, copies of cited pending unpublished applications that are available at the USPTO's private PAIR system are not submitted herewith.

This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b):

		continued prosecution application under §1.53(d);
		Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;
		☐ Before the mailing of the first Office action on the merits;
		Before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
3.	under (This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the specified in 37 C.F.R. §1.97(b), but before the mailing date of any of a final action 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that rise closes prosecution in the application.
		(Check either Item 3a or 3b)
	3a.	☐ The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.
	3b.	The \$180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is:
		enclosed.
		to be charged to Jones Day Deposit Account No. 50-3013.
		(Item 3b to be checked if any reference known for more than 3 months)
4.	period	This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the specified in 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee.
	The Co	ertification Statement in Item 5 below is applicable.
		The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is: enclosed.
	_	to be charged to Jones Day Deposit Account No. 50-3013.
5.		Certification Statement (applicable if Item 3a or Item 4 is checked):
		(Check either Item 5a or 5b)
	5a.	In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
	5b.	Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not received by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.
	5c.	Pursuant to 37 C.F.R. §1.704(d), each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not received by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.

6.		This application is a continuation application under 37 C.F.R. §1.53(b) or (d).
		(Check appropriate Items 6a, 6b and/or 6c)
	6a.	A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concurrently filed herewith.
	6b.	Copies of publications listed on Form PTO-1449 from prior application Serial No. , filed on , of which this application claims priority under 35 U.S.C. §120, are not being submitted pursuant to 37 C.F.R. §1.98(d).
	6c.	Copies of the publications listed on Form PTO-1449 were not previously cited in prior application Serial No. , filed on , and are provided herewith.
7.		This is a Supplemental Information Disclosure Statement. (Check Item 7a)
	7a.	This Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(f) supplements the Information Disclosure Statement filed on . A bona fide attempt was made to comply with 37 C.F.R. §1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental Information Disclosure Statement can be considered as if properly filed on .
8.	underst	In accordance with 37 C.F.R. §1.98, a concise explanation of what is presently good to be the relevance of each non-English language publication is:
		(Check Item 8a, 8b, or 8c)
	8a.	Satisfied because all non-English language publications were cited on the enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office.
	8b.	Set forth in the application.
	8c.	☐ Enclosed as an attachment hereto.
9.		The Commissioner is authorized to charge any additional fee required or credit any yment for this Information Disclosure Statement and/or Petition to Jones Day Deposit nt No. 50-3013.
10.	(other t	No admission is made that the information cited in this Statement is, or is considered naterial to patentability and no representation is made that a search has been made than a search report of a foreign counterpart application or PCT International Search if submitted herewith). 37 C.F.R. §§1.97(g) and (h).
		Respectfully submitted,
Date:	m	orch 2,2006 Brett Lovejoy (Reg. No.)
		JONES DAY 222 East 41st Street
		New York, New York 10017 (212) 326-3939

				ATTY. DOCKET NO. 11548-003-999			APPLICATION NO. 10/566,954			
LIST OF F	REFEI	(Use several sheets if		NT		PPLICANT Gustafsson et a	<u>1. </u>			
				FILING DATE January 31, 2006			GROUP To be assigned			
			U.S. PA	TENT D	OCUME				<u> </u>	***
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAM	Е	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	A01	US 2002/0177170 A1	11/28/2002	Luo et al.						
	A02	US 2002/0119492 A1	08/29/2002	Chirno et	al.					
	A03									
	A04									
	A05									
	A06									
	A07									
· · · · · · · · · · · · · · · · · · ·	A08									
	A09									
	A10									
	A11									
	A12									
		FOREIGN PATEN DOCUMENT NUMBER DATE			T DOCUI		CLASS	SUBCLASS	TRANSL	1
	B01	PCT/US04/24751	07/30/2004	PCT Sear	rch Report				YES	NO
	B02									
	B03				*******		_		 	
	B04									
	B05	······································								
	B06		<u> </u>							1
	B07									
	B08								1	
	B09					·····				
		OTHER REFER	ENCES (Incl	uding Aut	hor, Title,	Date, Pertine	nt Pages, I	Etc.)		
C01 Schneider et al., 1998, "Peptide design by artificial neural networks and computer-based evolutionary Vol. 95, Issue 21, pages 12179-12184							volutionary,'	'Biochem	nistry,	
	1									
	C02	71 3								
	C02 C03									
EXAMINER	C03	/Michae	el Borin/		DATE CO	NSIDERED	02/1:	2/2009	41.04	